Drug intelligence / Profile preview

pooled human immune globulin + serum tears + steroids

Development stage
Preclinical
Lead developer
Selagine
Modality
Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Recombinant Proteins and Enzymes, Hydrogel Systems → Drug Delivery Systems
Administration
Ophthalmic, Intravenous
01

Overview

This is a combination therapy consisting of three components: - Pooled human immune globulin (often administered as intravenous immunoglobulin, IVIG, or formulated as eye drops): a biologic product containing pooled IgG antibodies from the plasma of healthy donors. It exerts immunomodulatory effects by blocking Fc receptors and neutralizing pathogenic autoantibodies. - Serum tears (either autologous or allogeneic): eye drops made from blood serum, rich in growth factors, proteins, and immunoglobulins that mimic natural tear composition to promote ocular surface healing and reduce inflammation. - Steroids (corticosteroids): anti-inflammatory agents that suppress local immune responses on the ocular surface. This combination is used primarily for severe ocular surface diseases such as dry eye disease (DED), especially in cases associated with autoimmune conditions like Sjögren’s syndrome. The rationale for combining these therapies is to provide both immediate anti-inflammatory action (steroids), long-term immunomodulation (IVIG/immune globulin), and support for epithelial healing and tear film stability (serum tears). Each component has distinct but complementary mechanisms of action[1][3][5].

02

Targets

GR (Glucocorticoid receptor)EGFR (Epidermal growth factor receptor)FcγR (Low affinity immunoglobulin gamma Fc region receptor II-c)

Beyond the preview

Go deeper on pooled human immune globulin + serum tears + steroids.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on pooled human immune globulin + serum tears + steroids.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call